The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Directly Enhances the Contractile Recovery of Mouse Hearts at a Concentration Equivalent to that Achieved with Standard Dosing in Humans

The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Directly Enhances the Contractile Recovery of Mouse Hearts at a Concentration Equivalent to that Achieved with Standard Dosing in Humans

Despite a similar mechanism of action underlying their glucose-lowering effects in type 2 diabetes, dipeptidyl peptidase-4 (DPP-4) inhibitors have diverse molecular structures, raising the prospect of agent-specific, glucose-independent actions. To explore the issue of possible DPP-4 inhibitor cardi...

Full description

Bibliographic Details
Main Authors: Sri Nagarjun Batchu, Veera Ganesh Yerra, Youan Liu, Suzanne L. Advani, Thomas Klein, Andrew Advani
Format: Article
Language:English
Published: MDPI AG 2020-08-01
Series:International Journal of Molecular Sciences
Subjects:
DPP-4 inhibitor
linagliptin
Langendorff
nitric oxide
ischemia reperfusion injury
Online Access:https://www.mdpi.com/1422-0067/21/16/5756

Internet

https://www.mdpi.com/1422-0067/21/16/5756

Similar Items